Advertisement

Biomarkers in Cancer Therapy

Liquid Biopsy Comes of Age

  • Hideaki Shimada
Book

Table of contents

  1. Front Matter
    Pages i-viii
  2. Various Strategies to Detect Cancer

    1. Front Matter
      Pages 1-1
    2. Makoto Sumazaki, Koji Ueda
      Pages 3-10
    3. Hiroyuki Yamamoto, Yoshiyuki Watanabe, Fumio Itoh
      Pages 11-24
    4. Takaki Hiwasa, Hideaki Shimada
      Pages 25-40
    5. Hideaki Shimada
      Pages 41-49
    6. Norikatsu Miyoshi, Tsunekazu Mizusima, Yuichiro Doki, Masaki Mori
      Pages 51-59
  3. Biomarkers for Individual Cancers

    1. Front Matter
      Pages 61-61
    2. Shuhei Ito, Kensuke Koike, Koshi Mimori
      Pages 63-77
    3. K. Yamashita
      Pages 79-86
    4. Eiichiro Suzuki, Tetsuhiro Chiba, Naoya Kato
      Pages 87-95
    5. Takahiro Kishikawa, Minoru Tada, Motoyuki Otsuka, Kazuhiko Koike
      Pages 97-104
    6. Akihiko Miyanaga, Mari Masuda, Tesshi Yamada
      Pages 105-113
    7. Tetsu Hayashida, Yuko Kitagawa
      Pages 115-124
    8. Koichiro Akakura
      Pages 125-132
    9. Tatsuyuki Chiyoda, Ai Dozen, Keiko Saotome, Yoshiko Nanki, Daisuke Aoki
      Pages 133-150
    10. Kazutoshi Isobe
      Pages 151-157

About this book

Introduction

This book sheds new light on research into liquid biopsy biomarkers for cancer screening. The chapters in the first half address exosomes, circulating cell-free DNA and autoantibodies, and main solid cancers, along with companion biomarkers – all of which serve as the basis for exploring key research questions for future clinical trials in the book’s second half.

The study of biomarkers has evolved rapidly thanks to advances in precision medicine. While conventional cancer biomarker research is focused on proteomics or gene analysis of resected tissue, diagnostic markers have since become significant in terms of gauging the effectiveness of molecularly targeted drugs or the likelihood of a favorable prognosis. In addition, conventional treatment strategy, which draws on archives of resected tissue samples, is now gradually being replaced by monitoring with the use of liquid biopsy, which is poised to become the new mainstream in molecular targeting therapy.

The contributing authors discuss in detail biomarkers, molecular targets for treatment, monitoring markers to evaluate treatment responses, prognostic markers, and screening and early diagnosis. Accordingly, this excellent collection of texts will benefit not only oncologists, but also medical and biological researchers and pharmaceutical scientists involved in the latest cancer research.


Keywords

Cancer screening Exosomes Autoantibodies Molecular targeting therapy Precision medicine Clinical trial

Editors and affiliations

  • Hideaki Shimada
    • 1
  1. 1.Gastroenterology Center (Surgery)Toho University Omori Medical CenterTokyoJapan

Bibliographic information

  • DOI https://doi.org/10.1007/978-981-13-7295-7
  • Copyright Information Springer Nature Singapore Pte Ltd. 2019
  • Publisher Name Springer, Singapore
  • eBook Packages Medicine
  • Print ISBN 978-981-13-7294-0
  • Online ISBN 978-981-13-7295-7
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology
Oncology & Hematology